Marsico Capital Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

Marsico Capital Management’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q2	–	Sell	-266,171	Closed	-$18.2M	–	91
2014 Q1	$18.2M	Buy	266,171 +16,550	+7%	+$1.22M	0.13%	73
2013 Q4	$17.5M	Buy	249,621 +27,243	+12%	+$1.85M	0.12%	76
2013 Q3	$16.1M	Sell	222,378 -36,941	-14%	-$2.46M	0.12%	76
2013 Q2	$14.5M	Buy	+259,319	New	+$16.2M	0.09%	82

Other funds holding BMRN

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Marsico Capital Management's BMRN Position: Q2 2014 in Review

Marsico Capital Management sold out of BioMarin Pharmaceuticals (BMRN) in Q2 2014, closing a stake of 266,171 shares — an estimated $18.2M sold.

Marsico Capital Management first reported a position in BMRN in Q2 2013 and held it in 4 quarters. The position peaked at $18.2M in Q1 2014. 321 funds tracked by Wall St. Rank hold BMRN as of Q2 2014.

Marsico Capital Management reported no remaining BioMarin Pharmaceuticals position as of Q2 2014 after selling out during the quarter.
Marsico Capital Management sold 266,171 BioMarin Pharmaceuticals shares in Q2 2014, an estimated $18.2M.
Marsico Capital Management first reported a position in BioMarin Pharmaceuticals in Q2 2013 and held it in 4 quarters.
Marsico Capital Management's BioMarin Pharmaceuticals position peaked at $18.2M in Q1 2014.
321 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2014.

Based on Marsico Capital Management's 13F filing for Q2 2014, filed 14 Aug 2014.